Former Chief Operating Officer · LENZ Therapeutics, Inc. (LENZ)

Katherine Stultz

A named executive officer of LENZ Therapeutics in every fiscal year CompBrief holds from FY2020 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$2,516,347

Salary $408,333Stock awards $0

FY2020: $750,647

2nd of 3 named executive officers at Lenz Therapeutics by FY2021 total.

3 named officers on file for LENZ Therapeutics, FY2021

Katherine Stultz’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 3 equity grants, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how LENZ Therapeutics’s whole pay program stands against its peers

  • LENZ Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on LENZ→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2022 (DEF 14A).

Free

Get Katherine Stultz’s full pay file as a PDF — free

More than this page: up to 10 years of Katherine’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Katherine Stultz compensation by year

LENZ Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as LENZ Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021
Salary$133,333$408,333
Bonus$202,500$0
Stock awards$0$0
Option awards$414,814$1,905,014
Non-equity incentive$0$168,000
Pension and deferred compensation$0$0
All other$0$35,000
Total$750,647$2,516,347

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: LENZ Therapeutics, Inc. DEF 14A filed April 29, 2022, accession 0001193125-22-133540, and prior-year filings.

How this page was built: the LENZ Therapeutics, Inc. filed document, accession 0001193125-22-133540. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2022.

$751K
$2.5M
FY20
FY21
SalaryBonusNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
RSU138,596$1,722,748—
Option66,502—$0.30
Option170,500—$6.11
Option73,072—$6.11

Per the Outstanding Equity Awards at Fiscal Year-End table in LENZ Therapeutics, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

LENZ Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Josh LehrerPresident and Chief Executive Officer$7,922,159
Katherine Stultz · this pageFormer Chief Operating Officer$2,516,347
Philip GutryChief Business Officer$2,088,030

The full LENZ Therapeutics compensation record

free company brief

This page is one person within LENZ Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are LENZ Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Katherine Stultz's compensation dossier · One-time report. No refunds.